Kat Attica General Hospital

Research site

Greece Nikis 2, 145 61 Kifissia, Greece

8 trials recruiting
Back pain · Acute myocardial infarction · Arteriosclerosis
Adult patients

About Specializations

Kat Attica General Hospital in Kifissia, Greece specialises in clinical trials of conditions such as Back pain, Acute myocardial infarction, Arteriosclerosis, Atrial fibrillation, and other specialisations. This site conducts important research.

Main research areas of the site

Sepsis and Interferon-Gamma Endotype

The medical center is at the forefront of research in sepsis, particularly focusing on the Interferon-Gamma Endotype (IDS). This specific endotype is identified as a significant risk factor for increased mortality in sepsis patients, independent of infection type or comorbidities.

Interferon-Gamma Blockade
Monoclonal Antibody Therapies
Endotype-Specific Treatment

The center's research aims to improve patient outcomes by utilizing emapalumab, a monoclonal antibody that targets and blocks IFNγ, potentially reducing mortality rates in this patient subset.

Acute Low Back Pain Management

Specializing in the treatment of acute moderate to severe low back pain, the center is exploring the efficacy of combination therapies. The focus is on enhancing pain relief through innovative injectable solutions.

Combination Therapy Efficacy
Pain Management Techniques
Patient-Reported Outcomes

By comparing the effectiveness of a combination of thiocolchicoside and diclofenac against diclofenac alone, the center aims to establish superior pain management protocols for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Nikis 2145 61 KifissiaGreece

Open in maps ↗

Recruiting now: 8 trials
Conditions studied: 15

More sites in Kifissia Greece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

16 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Greece

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Pneumonia bacterial

Recruiting

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Ampicillin Sodium
Sponsor:Bioversys S.A.S.

Contact Research Centre

Back pain

Recruiting

Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Registered drug

Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Diclofenac potassium
Sponsor:Verisfield Single Member S.A.

Contact Research Centre

Back pain

Recruiting

Study comparing diclofenac, orphenadrine and paracetamol combination versus diclofenac alone and orphenadrine-paracetamol combination in patients with acute low back pain

Registered drug

Study comparing diclofenac, orphenadrine and paracetamol combination versus diclofenac alone and orphenadrine-paracetamol combination in patients with acute low back pain

Registered drug

Greece

Participants:18–64 years
Substances:Diclofenac potassium
Sponsor:Verisfield Single Member S.A.

Contact Research Centre

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting

Investigational

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Finerenone
Sponsor:Colorado Prevention Center

Contact Research Centre

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Atrial fibrillation+1

Not recruiting

Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

Registered drugNo placebo

Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Flecainide Acetate
Sponsor:Win Medica Pharmaceutical S.A.

Contact Research Centre

Back pain

Not recruiting

Study Comparing Diclofenac and Thiocolchicoside Injection to Diclofenac Alone for Patients with Acute Moderate to Severe Low Back Pain

Registered drugNo placebo

Study Comparing Diclofenac and Thiocolchicoside Injection to Diclofenac Alone for Patients with Acute Moderate to Severe Low Back Pain

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Diclofenac Sodium
Sponsor:Verisfield Single Member S.A.

Contact Research Centre

Pneumonia

Not recruiting

Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drug

Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites